2023
Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer
Williams N, Quiroga D, Johnson C, Brufsky A, Chambers M, Bhattacharya S, Patterson M, Sardesai S, Stover D, Lustberg M, Noonan A, Cherian M, Bystry D, Hill K, Chen M, Phelps M, Grever M, Stephens J, Ramaswamy B, Carson W, Wesolowski R. Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer. Therapeutic Advances In Medical Oncology 2023, 15: 17588359231217976. PMID: 38152697, PMCID: PMC10752118, DOI: 10.1177/17588359231217976.Peer-Reviewed Original ResearchAdvanced triple-negative breast cancerTriple-negative breast cancerProgression-free survivalDuration of responseOverall response ratePrior taxane therapyAdverse eventsTaxane therapyCombination therapyBreast cancerMedian DORMedian progression-free survivalNon-hematologic adverse eventsPhase Ib studyPhase Ib trialPhase II doseAcceptable toxicity profileDose-limiting toxicityDrug interaction profileIb trialIntravenous paclitaxelPaclitaxel efficacyExpansion cohortCombination regimenMetastatic disease
2019
350P Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173)
Wesolowski R, Brufsky A, Chambers M, Bhattacharya S, Lustberg M, VanDeusen J, Sardesai S, Williams N, Noonan A, Phelps M, Grever M, Stephens J, Carson W, Ramaswamy B. 350P Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173). Annals Of Oncology 2019, 30: v126. DOI: 10.1093/annonc/mdz242.045.Peer-Reviewed Original ResearchTriple-negative breast cancerOverall response rateNegative breast cancerBreast cancerDay 1Cancer Therapy Evaluation ProgramCycle 1Clinical benefit rateCommon grade 3Dose level 1Dose-expansion studyHigher adverse eventsPhase Ib studySchedule of paclitaxelAcceptable safety profileProgression-free survivalHeat shock protein 90 inhibitorShock protein 90 inhibitorsNational Cancer InstituteEvaluable ptsPaclitaxel hypersensitivityStudy regimenAdverse eventsMethods PatientsSafety profile
2017
Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173).
Wesolowski R, Lustberg M, Reinbolt R, VanDeusen J, Sardesai S, Williams N, Noonan A, Dewani S, Poi M, Wilson D, Grever M, Stephens J, Puhalla S, Mathew A, Carson W, Ramaswamy B. Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173). Journal Of Clinical Oncology 2017, 35: tps1127-tps1127. DOI: 10.1200/jco.2017.35.15_suppl.tps1127.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerDay 1Hormone receptor-positive breast cancerReceptor-positive breast cancerPhase Ib studyPhase II doseProgression-free survivalPositive breast cancerOverall response rateHeat shock protein 90 inhibitorNegative breast cancerCycle 1Shock protein 90 inhibitorsPoor outcomeStandard doseAndrogen receptorHsp90 client proteinsHeat shock protein 90Ib studyResponse durationToxicity profilePaclitaxel resistanceClient proteinsDay 7